U.S. Stock News

Shareholders in Amphenol Corporation ( NYSE:APH ) may be thrilled to learn that the analysts have just delivered a...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Amdocs fair value estimate is US$130 Amdocs is estimated to be...

If you are wondering whether Boston Beer Company at around US$209.82 is a bargain or a value trap, you are not alone. That is exactly what this article tackles. The stock has returned 3.8% over the last 7 days and 3.3% over the last 30 days, although its 1 year return of a 19.0% decline and 5 year return of a 77.1% decline show a very different picture. Recent coverage has focused on how craft beer brands are competing for shelf space and how consumer tastes are shifting across beer, hard...

Allison Transmission Holdings has reorganized into two business units, Allison Transmission and Allison Off-Highway Drive & Motion Systems, with Fred Bohley and newly appointed executive Craig Price leading the units and reporting to CEO David Graziosi. The hiring of Price from Dana’s Off-Highway business, alongside his long tenure in purchasing and supplier development, signals a push to tightly manage costs and extract efficiencies from the recently acquired operations. Next, we’ll examine...

Baird’s downgrade of Sunstone Hotel Investors (SHO) from Outperform to Neutral puts fresh attention on the REIT’s positioning versus peers, particularly given its consistent dividend history and current 3.82% yield. See our latest analysis for Sunstone Hotel Investors. The Baird downgrade comes after a mixed run for the stock, with a 1-day share price return of 1.08% and a 30-day share price return of 1.30%, set against a 1-year total shareholder return decline of 16.11%. Taken together, this...

Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking. This high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers. With this conference spotlight and recent share price...

Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-year 2025 results indicating approximately 12% quarterly and 9% annual revenue growth. Management also highlighted a record level of incremental contract value from new and expanded hospital agreements, underscoring the importance of long-term customer relationships to the business. We’ll now examine how the record incremental...

Honat Bancorp (HONT) has put another solid quarter on the board, with Q2 2025 revenue of US$11.4 million and basic EPS of US$2.57 feeding into trailing twelve month EPS of US$10.46 on revenue of US$44.6 million and net income of US$15.0 million. Over the past year, the company has seen revenue move from US$38.8 million to US$44.6 million on a trailing basis, while EPS climbed from US$8.33 to US$10.46, and earnings growth of 19% has supported a net profit margin of 33.5% compared with 31.2% a...

If you are wondering whether Fidelity National Information Services is priced attractively right now, you are not alone. Many investors are asking if the current share price lines up with the company’s underlying value. The stock recently closed at US$64.23, with returns of a 4.2% decline over 7 days, a 4.3% decline over 30 days, a 2.1% decline year to date, a 16.2% decline over 1 year, and a 44.0% decline over 5 years, which may influence how you think about its potential and its...

Immunovant (IMVT) has been drawing attention after recent share moves that contrast a loss-making profile with fast annual growth in revenue and net income metrics, raising questions about how investors are weighing its clinical-stage risks. See our latest analysis for Immunovant. At a share price of $26.18, Immunovant’s recent 1 day share price return of 1.43% and 90 day share price return of 46.01% sit alongside a 1 year total shareholder return of 14.42% and 3 year total shareholder return...

If you are wondering whether J. M. Smucker's current share price fairly reflects its long term value, you are not alone. This article is built to unpack exactly that question. The stock last closed at US$101.61, with returns of 5.9% over the past 7 days, 5.2% year to date and 3.8% over the last year. The 3 year return sits at a 27.3% decline and the 5 year return at 3.7%. Recent coverage around J. M. Smucker has focused on its position in packaged foods and consumer staples, as investors...

JPMorgan Chase (JPM) has capped FY 2025 with fourth quarter revenue of US$41.1b and basic EPS of US$4.64, alongside net income of US$12.7b, setting a clear marker for how the bank is exiting the year. The company has seen revenue move from US$40.1b in Q4 2024 to US$41.1b in Q4 2025, while quarterly EPS went from US$4.82 to US$4.64 over the same period, giving you a clean year on year reference point for the top and bottom line. With trailing net profit margins sitting just below last year and...

If you are wondering whether CareTrust REIT's share price still offers value at around US$37.36, you are not alone; many investors are asking the same question. The stock has returned 1.9% over the last week, 2.9% over the last month, 2.9% year to date, 46.5% over the last year, 121.3% over three years, and 113.7% over five years. This naturally raises questions about what is already reflected in the price. Recent attention on CareTrust REIT has focused on its position within the healthcare...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...

Wealthfront (WLTH) just posted its Q3 2026 numbers, with revenue of US$93.2 million, basic EPS of US$0.72 and trailing twelve month EPS of US$3.04 setting the backdrop for the quarter. The company has seen revenue move from US$80.3 million in Q3 2025 to US$93.2 million in Q3 2026, while quarterly EPS has shifted from US$0.77 to US$0.72 over the same period, against trailing twelve month revenue of US$351.5 million. With a current net profit margin of 35.2% versus 57.7% a year ago, this update...

Village Farms International (VFF) has drawn fresh attention after its Leli Holland unit rolled out ten new cannabis products into the regulated Dutch market, including the country’s first licensed blunt and several tailored spliff formats. See our latest analysis for Village Farms International. At a share price of $3.50, Village Farms International has seen a 30 day share price return decline of 14.22% and a year to date share price return decline of 5.15%. Its 1 year total shareholder...

3D Systems recently presented at the 28th Annual Needham Growth Conference while highlighting expanded Aerospace & Defense operations, new FDA clearance for its VSP Orthopedics platform, and balance-sheet strengthening through equity-funded debt reduction. Together, the push into defense-focused manufacturing, broader orthopedic indications, and efforts to reinforce the capital structure underscore how the company is repositioning around mission-critical, higher-value applications. We’ll now...

If you are wondering whether CoreCivic’s share price still offers value at around US$19.94, you are not alone. This article focuses squarely on what that price could mean for investors. The stock has returned 5.2% over the last 7 days, 5.5% over the last 30 days, 4.8% year to date, while its 1 year return of a 10.7% decline sits against a 76.8% return over 3 years and 173.9% over 5 years. Recent headlines around CoreCivic have continued to keep the company in focus, with investors weighing...

Crinetics Pharmaceuticals recently completed a US$350.14 million follow-on common stock offering after reporting over US$5 million in preliminary fourth-quarter 2025 PALSONIFY revenue and positive Phase 2 atumelnant data in classic congenital adrenal hyperplasia. Together, these updates highlight early commercial traction for PALSONIFY and clinical progress for atumelnant, while the equity raise may bolster Crinetics’ ability to fund further development and commercialization. We’ll now...

Delta Air Lines (DAL) has just wrapped up FY 2025 with Q4 revenue of US$16.0b and basic EPS of US$1.88, alongside net income excluding extra items of US$1,219m. Over the past year, revenue on a trailing twelve month basis moved from US$61.6b with EPS of US$5.39 to US$63.4b with EPS of US$7.72, while trailing net income excluding extra items rose from US$3,457m to US$5,005m. For investors, the current earnings outline a picture of firmer margins and profitability that now need to be weighed...

Caris Life Sciences (CAI) recently announced a partnership with Everlywell to launch Caris Detect, a multi cancer early detection blood test that uses whole genome sequencing and AI analysis. See our latest analysis for Caris Life Sciences. Despite the Everlywell partnership and recent preliminary 2025 numbers that highlighted revenue growth and higher case volumes, momentum in Caris Life Sciences' share price has been soft. The 90 day share price return is 15.28% and the year to date share...

Autolus Therapeutics recently reported preliminary unaudited 2025 net product revenue of about US$75 million and issued 2026 guidance of US$120 million to US$135 million, alongside progressing obe-cel into Phase 2 trials for lupus nephritis and other indications. The company also secured UK and EU approvals for AUCATZYL®, pairing early commercial traction with expanding clinical data in both pediatric oncology and autoimmune disease. Next, we’ll examine how this combination of higher revenue...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...